1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Shutter R&D Subsidiary in Tokyo in Group Rejig
August 8, 2023
- Iveric Bio’s AMD Drug Approved in US, Launch Set for This Month: Astellas
August 8, 2023
- Global PIII Study for Zipalertinib Begins for 1st Line NSCLC: Taiho
August 8, 2023
- Nippon Shinyaku’s DMD Therapy Gets Orphan Tag in US
August 8, 2023
- Kyowa Kirin Chief Admits Difficulties in Trial Design Felt with Dumped Kidney Disease Med
August 7, 2023
- Wakamoto Seeks to Add New Manufacturer for MaQaid amid Supply Woes
August 7, 2023
- Mitsubishi Tanabe Aims to Maximize Value of Mounjaro through Synergies with Other Products
August 4, 2023
- Kyowa Kirin’s 6-Month Sales Up 7.5% as Global Brands Log Positive Growth
August 4, 2023
- Rakuten Medical Gears Up for Global Pitch on Photoimmunotherapy: Chairman
August 4, 2023
- Lonsurf-Bevacizumab Snags US Approval for Colorectal Cancer: Taiho
August 4, 2023
- Opdivo Tops Japan Sales Ranking for 19 Months on End: Encise
August 4, 2023
- Eisai Sees Positive Shift in US Market for Leqembi after Full Approval: Exec
August 3, 2023
- Sumitomo to Focus on 3 Core Products in North America to Overcome Latuda Patent Cliff: President
August 3, 2023
- Mitsubishi Tanabe’s Q1 Sales Up 3.8% on Back of Bullish Oral Radicava Sales in US
August 3, 2023
- Pfizer’s Bivalent COVID Vaccines Approved for Primary Series in Japan
August 3, 2023
- Eligibility Age of Moderna COVID Vaccine Lowered to 6 and Older
August 3, 2023
- Moderna Japan’s XBB-Based COVID Jab Actually Filed for Age 6 and Up
August 3, 2023
- Japan OKs 1st Homemade COVID Jab, but No Supply Planned; Daiichi to Pursue XBB.1 Update
August 3, 2023
- Eisai’s Q1 Operating Profit Jumps on Lenvima Growth, Lower Aduhelm Cost
August 3, 2023
- Japan Greenlights Shionogi’s Stable Supply Plan for 2 Cephalosporin Antibiotics
August 2, 2023
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…